Skip to main content

Addex Therapeutics Ltd.

corporate_fare Company Profile

Addex Therapeutics Ltd.

ADXN·NASDAQ·Life Sciences·CIK 0001574232

Addex Therapeutics Ltd. is a Swiss limited company founded in 2002, operating as a clinical-stage pharmaceutical company. The company focuses on developing a portfolio of new orally available small molecule drug candidates. Its business includes a pipeline of proprietary drug candidates at both clinical and preclinical stages, which are being developed either by Addex Therapeutics or its partners. These drug candidates target diseases with no approved therapies or where better treatments are needed, such as post-stroke sensorimotor recovery, traumatic brain injury (TBI) recovery, substance use disorders (SUD), and chronic cough. Addex Therapeutics also holds a 20% equity interest in Neurosterix US Holdings LLC, a private spin-out company that is developing a portfolio of preclinical stage proprietary drug candidates for schizophrenia and mood disorders. The company's primary development compound is dipraglurant, a metabotropic glutamate receptor subtype 5 negative allosteric modulator (mGlu5 NAM), which is currently being evaluated for future development in post-stroke/TBI recovery.

Addex Therapeutics Ltd. (NASDAQ:ADXN) is a publicly traded company in the Life Sciences sector. Wiseek monitors ADXN SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Addex Therapeutics Seeks Shareholder Approval to Increase Capital for Future Funding
  • Addex Therapeutics Reports Critical Going Concern Warning, Low Cash, and Material Internal Control Weakness in Annual Report
  • Addex Therapeutics Reports Significant FY2025 Net Loss of CHF 6.7M; Cash Dwindles to CHF 1.6M
  • Addex Reports CHF 6.7M Net Loss for 2025, Cash Balance Drops to CHF 1.6M
  • Addex Therapeutics Reports Positive Preclinical Data for GABAB PAM in Chronic Cough Model

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
CHF 29.97K CHF
Net Income
-CHF 6.73M CHF
Diluted EPS
-CHF 0.06 CHF
Op. Cash Flow
-CHF 2.17M CHF
Free Cash Flow
-CHF 2.17M CHF
Operating Income
-CHF 2.81M CHF
Cash & Equivalents
CHF 1.64M CHF
Total Debt
CHF 0 CHF
Debt / Equity
0.00×
Net Margin
-224.48×
Shares Outstanding
147.83M sh
Source: 20-F · filed 2026-05-15 · accession 0001104659-26-062447

Insider Transactions

ADXN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with A →
$6.5
52-week range · as of 2026-06-05 $5.41 – $12.05
Market cap
$6.08M
Volume
21.4K (5.6× avg)
3-mo avg 3.8K
Live data · 2026-06-14 03:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ADXN - Latest Insights

ADXN
Jun 05, 2026, 6:05 AM EDT
Filing Type: 6-K
Importance Score:
8
Addex Therapeutics Seeks Shareholder Approval to Increase Capital for Future Funding
Price at Filing: $6.70
Real-time Price: $6.50 info
Change: -$0.200 (-3%) info
Market Cap: $6.082M info
Sentiment: Negative
View Wiseek Article
ADXN
May 15, 2026, 4:00 PM EDT
Filing Type: 20-F
Importance Score:
9
Addex Therapeutics Reports Critical Going Concern Warning, Low Cash, and Material Internal Control Weakness in Annual Report
Price at Filing: $6.81
Real-time Price: $6.50 info
Change: -$0.310 (-5%) info
Market Cap: $6.082M info
Sentiment: Negative
View Wiseek Article
ADXN
Apr 30, 2026, 6:05 AM EDT
Filing Type: 6-K
Importance Score:
8
Addex Therapeutics Reports Significant FY2025 Net Loss of CHF 6.7M; Cash Dwindles to CHF 1.6M
Price at Filing: $7.11
Real-time Price: $6.50 info
Change: -$0.610 (-9%) info
Market Cap: $6.082M info
Sentiment: Negative
View Wiseek Article
ADXN
Apr 30, 2026, 1:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Addex Reports CHF 6.7M Net Loss for 2025, Cash Balance Drops to CHF 1.6M
Price at Filing: $7.11
Real-time Price: $6.50 info
Change: -$0.610 (-9%) info
Market Cap: $6.082M info
Sentiment: Negative
View Wiseek Article
ADXN
Apr 29, 2026, 6:05 AM EDT
Filing Type: 6-K
Importance Score:
7
Addex Therapeutics Reports Positive Preclinical Data for GABAB PAM in Chronic Cough Model
Price at Filing: $6.90
Real-time Price: $6.50 info
Change: -$0.400 (-6%) info
Market Cap: $6.082M info
Sentiment: Positive
View Wiseek Article
ADXN
Apr 29, 2026, 1:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Addex GABAB PAM Candidate Shows Solid Anti-Tussive Activity in IPF Chronic Cough Model
Price at Filing: $6.74
Real-time Price: $6.50 info
Change: -$0.240 (-4%) info
Market Cap: $6.082M info
Sentiment: Positive
View Wiseek Article
ADXN
Apr 21, 2026, 1:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Addex's Chronic Cough Drug Candidate Shows Robust Efficacy in Non-Human Primate Study
Price at Filing: $7.30
Real-time Price: $6.50 info
Change: -$0.800 (-11%) info
Market Cap: $6.082M info
Sentiment: Positive
View Wiseek Article
ADXN
Feb 03, 2026, 6:05 AM EST
Filing Type: 6-K
Importance Score:
7
Addex Spin-Out Neurosterix Publishes Preclinical Data for Anxiety Treatment
Price at Filing: $7.66
Real-time Price: $6.50 info
Change: -$1.16 (-15%) info
Market Cap: $6.082M info
Sentiment: Positive
View Wiseek Article
ADXN
Jan 07, 2026, 6:05 AM EST
Filing Type: 6-K
Importance Score:
7
Addex Spin-Out Neurosterix Initiates Phase 1 Clinical Study for Schizophrenia Drug NTX-253
Price at Filing: $8.09
Real-time Price: $6.50 info
Change: -$1.59 (-20%) info
Market Cap: $6.082M info
Sentiment: Positive
View Wiseek Article